Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)


Cite item

Full Text

Abstract

The aim of the study was to evaluate the effect of the drug therapy assigned at the index visit on the risk of fatal outcome in outpatients with coronary heart disease within 24 months from the index visit, based on the data of registry of cardiovascular diseases (RECVASA). Follow-up feedback was 97.4%, the survival rate - 90.6%. The study found that the prescribing of angiotensin-converting enzyme (ACE) inhibitors or ACE inhibitors/angiotensin receptor blockers II (ARB) was associated with reduction of all-cause mortality by 1.6 times (p=0.016) and 2.0 times (p=0.006), respectively, statins - by 1.6 times (p=0.038). The risk of death from cardiovascular causes in the case of prescribing of ACE inhibitors or ACE inhibitors/ARBs decreased by 2.1 times (p=0.0008) and 2.3 times (p=0.0008), respectively, statins - by 1,7 times (p=0.048).

About the authors

K. G Pereverzeva

I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation

Email: pereverzevakg@gmail.com
канд. мед. наук, ассистент каф. госпитальной терапии 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9

S. S Yakushin

I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation

проф., д-р мед. наук, зав. каф. госпитальной терапии 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9

A. N Vorobyev

I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, ассистент каф. госпитальной терапии 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9

M. M Lukyanov

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

канд. мед. наук, вед. науч. сотр. отд. клинической кардиологии и молекулярной генетики 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

E. Yu Andreyenko

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд. клинической кардиологии и молекулярной генетики 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

A. V Zagrebelny

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд. профилактической фармакотерапии 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

A. D Deev

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

канд. физ.-мат. наук, рук. лаб. биостатистики 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Демографический ежегодник России, 2014. Сб. ст. Росстат. http://www.gks.ru/bgd/regl/B14_16
  2. Демография. http://www.gks.ru/wps/wcm/connect/rosstat_main/ rosstat/ru/statistics/population/demography
  3. Бойцов С.А. и др. Регистры в кардиологии. Основные правила проведения и реальные возможности. Кардиоваскулярная терапия и профилактика. 2013; 12 (1): 4-9
  4. Марцевич С.Ю. и др. Регистры как способ изучения эффективности и безопасности лекарственных препаратов. Клиницист. 2012; 3 (4): 4-10.
  5. Бойцов С.А. и др. Амбулаторно-поликлинический регистр РЕКВАЗА: данные проспективного наблюдения, оценка риска и исходы у больных с кардиоваскулярными заболеваниями. Кардиоваскулярная терапия и профилактика. 2015; 14 (1): 53-62.
  6. Переверзева К.Г. и др. Особенности обследования пациентов с ишемической болезнью сердца в амбулаторной практике по данным регистрового наблюдения. Рос. медико-биологичекий вестн. им. акад. И.П.Павлова. 2014; 1: 90-6
  7. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 1670-81.
  8. Savarese G. и др. Мета-анализ исследований, сообщавших об эффектах ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов ангиотензина у больных без сердечной недостаточности. Рациональная фармакотерапия в кардиологии. 2013; 9 (2): 188-200.
  9. Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Prefer redreporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
  10. Savarese G, Costanzo P, Cleland J.G. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013; 61: 131-42.
  11. Ong H.T, Ong L.M, Ho J.J. Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiol 2013; 2013: 478597.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies